Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lymphoma 8Lung Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Hodgkin Disease 6Recurrence 3Kidney Neoplasms 2Urinary Bladder Neoplasms 1Testicular Neoplasms 1Teratoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1Ovarian Neoplasms 1Ovarian Germ Cell Cancer 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Melanoma 1Lymphoma, Large-Cell, Anaplastic 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1HIV Infections 1Carcinoma, Renal Cell 1Acquired Immunodeficiency Syndrome 1AIDS-Related Complex 1

Interventions

pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1merphos 1durvalumab 1Vinblastine 1Specimen Handling 1Platinum 1Methotrexate 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Gemcitabine 1Doxorubicin 1Disulfides 1Cisplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Renal Pelvis and Ureter Urothelial Carcinoma × Vinblastine × Clear all
NCT04628767 2026-06-03

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
131 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡